Skip to main content
. 2022 Jul 14;15:92. doi: 10.1186/s13045-022-01302-7

Fig. 1.

Fig. 1

A. Change in mean blood pressure during acalabrutinib treatment over the 60-month study period; standard deviation represented by error bars. B. Cumulative incidence of new hypertension (HTN) across time following acalabrutinib initiation. C. Cumulative incidence of worsened HTN across time following acalabrutinib initiation